

GLAXOSMITHKLINE PLC
Form 6-K
January 09, 2009

FORM 6-K

**SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549**

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For period ending January 2009

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons Discharging Managerial Responsibility or Connected Persons in the Ordinary shares of GlaxoSmithKline plc

in respect of the under-mentioned person

s arising from the purchase of Ordinary shares at a price of £ 12.82 per Ordinary share on 8 January 2009

through the Company

's ShareReward Plan (" the Plan ")

which the under-mentioned persons entered on 5 October 2001:

Mr A P Witty Acquisition of 20 Ordinary shares under the Dividend Reinvestment element of the Plan

Mr J S Heslop Acquisition of 20 Ordinary shares under the Dividend Reinvestment element of the Plan

Mr S M Bicknell Acquisition of 20 Ordinary shares under the Dividend Reinvestment element of the Plan

Mr E J Gray	Acquisition of 20 Ordinary shares under the Dividend Reinvestment element of the Plan
Mr D Learmouth	Acquisition of 20 Ordinary shares under the Dividend Reinvestment element of the Plan
Dr D Pulman	Acquisition of 8 Ordinary shares under the Dividend Reinvestment element of the Plan
Mr D S Redfern	Acquisition of 20 Ordinary shares under the Dividend Reinvestment element of the Plan
Ms C Thomas	Acquisition of 20 Ordinary shares under the Dividend Reinvestment element of the Plan

The Company and the above-mentioned persons were advised of this information on

9 January 2009

This notification relates to a transaction notified in accordance with

Disclosure
and Transparency
Rule 3.1.4R(1)(a)

V A Whyte
Deputy Company Secretary
9 January 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GlaxoSmithKline plc
(Registrant)

Date: January 09 2009

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc